FDA plans ultra-fast review of three psychedelic drugs following Trump directive
Headline from WHEC Rochester
The Food and Drug Administration says it will offer ultra-fast review to three psychedelic drugs being studied for hard-to-treat mental health conditions, including major depression. The agency announced the move Friday, following an executive order by President Donald Trump calling for the agency t…
WHEC Rochester's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
The Food and Drug Administration says it will offer ultra-fast review to three psychedelic drugs being studied for hard-to-treat mental health conditions, including major depression. The agency announced the move Friday, following an executive order by President Donald Trump calling for the agency t…
WASHINGTON (AP) — The Food and Drug Administration said Friday it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, including depression, the
The Food and Drug Administration says it will offer ultra-fast review to three psychedelic drugs being studied for hard-to-treat mental health conditions, including depression.
The U.S. Food and Drug Administration is seeking to accelerate the review process for three companies that are studying psilocybin and an MDMA-like drug as treatments for depression and PTSD
The Food and Drug Administration on Friday granted a quick review of three experimental psychedelic drugs meant to treat major depression and post-traumatic stress disorder.
